Company has cash and cash equivalent of S$24,696,000 against debt of S$25,385,000.
Check out their assets. I recall more than 70% of their assets are " goodwill" . This company may fall if banks start tightening on loans. Already, they had to convert their 9.6m issued bond (debt) to shares. If you ask me, this is not a financially healthy company.
n3wbie ( Date: 14-Nov-2019 23:49) Posted:
|
from a valuation gap perspective, SMG is trading some 80% lower than peers in terms of PE multiple (~12x vs 22x) so i' m not sure how the analysts arrive at a fair value of 36c. different strokes for different folks. 
calvinlooi ( Date: 13-Nov-2019 18:05) Posted:
|
Lack of M& A as catalysts? I remember there is still a lot of proceeds from right issue that is intended for M& A.
Maybe RHB want to accumulate some themself.
Maybe RHB want to accumulate some themself.
what' s interesting is that they highlighted the valuation of 12.2x PE which is distinctly cheaper than the peer group of 22x yet they decided to focus on the fact that there' s a lack of M& A as catalysts. kinda easy for analysts to just focus on low hanging fruits and not appreciate how difficult it is for management and companies to integrate and grow businesses
josephyeo ( Date: 13-Nov-2019 16:39) Posted:
|
RHB downgrades SingMedical from buy to " neutral" w a target price of 36.0 Cts.
RHB Invest has a buy recommendation. Target price 48 cts.
SingM is currently undervalued due to right issue a year ago. The takeover price has suggested that the company shares did worth $0.605.
Once the handover by existing shareholders to CHA is completed, it will back to normal.
Good to see change of management, those previous shareholders and directors only care about own interest instead of rewarding the public.
Once the handover by existing shareholders to CHA is completed, it will back to normal.
Good to see change of management, those previous shareholders and directors only care about own interest instead of rewarding the public.
Share some figures on SingMedical:
Datas on profits n revenues.
 
 
Revenue has grown fron S$41.5 mil to S$85.0 mil, a growth of above 100%
Profit has grown even higher, from S$2.4 mil to S$12.9 mil mil, a growth of 433%
Price history
52 weeks high - 49.5 cts
52 weeks low - 27.5 cts
At date of post - 32.0 cts.
Above for sharing only.
Vested
Datas on profits n revenues.
 
| singmedical | FY' 16 | FY' 17 | FY' 18 | 1H ' 19 |
| revenue (1000) | 41580 | 68001 | 85,069 | 44,643 |
| net profit (1000) | 2423 | 8499 | 12,928 | 6,843 |
Revenue has grown fron S$41.5 mil to S$85.0 mil, a growth of above 100%
Profit has grown even higher, from S$2.4 mil to S$12.9 mil mil, a growth of 433%
Price history
52 weeks high - 49.5 cts
52 weeks low - 27.5 cts
At date of post - 32.0 cts.
Above for sharing only.
Vested